» Articles » PMID: 24642799

Renal Involvement in Antiphospholipid Syndrome

Overview
Journal Nat Rev Nephrol
Specialty Nephrology
Date 2014 Mar 20
PMID 24642799
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Antiphospholipid syndrome (APS) is an autoimmune disease defined by the presence of arterial or venous thrombotic events and/or pregnancy morbidity in patients who test positive for antiphospholipid antibodies (aPLs). APS can be isolated (known as primary APS) or associated with other autoimmune diseases, such as systemic lupus erythematosus (SLE; known as secondary APS). The kidney is a major target organ in APS and renal thrombosis can occur at any level within the vasculature of the kidney (renal arteries, intrarenal arteries, glomerular capillaries and renal veins); events reflect the site and size of the involved vessels. Histological findings vary widely, including ischaemic glomeruli and thrombotic lesions without glomerular or arterial immune deposits on immunofluorescence. Renal prognosis is affected by the presence of aPLs in patients with lupus nephritis and can be poor. In patients with SLE and aPLs, biopsy should be performed because inflammatory and thrombotic lesions require different therapeutic approaches. Renal involvement in patients with definite APS is treated by anticoagulation with long-term warfarin. The range of renal manifestations associated with APS is broadening and, therefore, aPLs have increasing relevance in end-stage renal disease, transplantation and pregnancy.

Citing Articles

The risk of thromboembolic events in patients with nephrotic syndrome and relatively high albumin levels: a study over 10 years.

Liu Y, Gao S, Liu L BMC Nephrol. 2024; 25(1):301.

PMID: 39261806 PMC: 11389433. DOI: 10.1186/s12882-024-03704-w.


Causal relationship between gut microbiota and kidney diseases: a two-sample Mendelian randomization study.

Feng Z, Zhang Y, Lai Y, Jia C, Wu F, Chen D Front Immunol. 2024; 14:1277554.

PMID: 38283353 PMC: 10811222. DOI: 10.3389/fimmu.2023.1277554.


Lupus Nephritis Biomarkers: A Critical Review.

Alduraibi F, Tsokos G Int J Mol Sci. 2024; 25(2).

PMID: 38255879 PMC: 10815779. DOI: 10.3390/ijms25020805.


An update on the biologics for the treatment of antiphospholipid syndrome.

Yun Z, Duan L, Liu X, Cai Q, Li C Front Immunol. 2023; 14:1145145.

PMID: 37275894 PMC: 10237350. DOI: 10.3389/fimmu.2023.1145145.


Clinical-Pathological Characteristics of Renal Injuries Identify Different Clusters in Patients With Antiphospholipid Antibodies.

Sciascia S, Yazdany J, Moroni G, Becker J, Seshan S, Andrade D Kidney Int Rep. 2023; 8(4):754-763.

PMID: 37069974 PMC: 10105059. DOI: 10.1016/j.ekir.2023.01.018.


References
1.
Ribera L, Vallve M, Almirall J . [Primary antiphospholipid syndrome associated with malignant hypertension]. Nefrologia. 2004; 24 Suppl 3:93-6. View

2.
Sirvent A, Enriquez R, Antolin A, Cabezuelo J, Gonzalez C, Arenas M . Malignant hypertension and antiphospholipid syndrome. Nephron. 1996; 73(2):368-9. DOI: 10.1159/000189092. View

3.
Prieto L, Suki W . Frequent hemodialysis graft thrombosis: association with antiphospholipid antibodies. Am J Kidney Dis. 1994; 23(4):587-90. DOI: 10.1016/s0272-6386(12)80383-0. View

4.
Moroni G, Ventura D, Riva P, Panzeri P, Quaglini S, Banfi G . Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis. 2004; 43(1):28-36. DOI: 10.1053/j.ajkd.2003.09.011. View

5.
Amigo M, Garcia-Torres R . Morphology of vascular, renal, and heart lesions in the antiphospholipid syndrome: relationship to pathogenesis. Curr Rheumatol Rep. 2000; 2(3):262-70. DOI: 10.1007/s11926-000-0089-4. View